Has Bret Bahn, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,216 in general payments to Bret Bahn, MD across 576 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bret Bahn, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bret Bahn, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bret Bahn, MD

Interventional Pain Medicine · Findlay, OHNPI 1003887043

Payments from drug & device makers

$13,216in general payments, 2019–2025

Across 576 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$4K
Boston Scientific$2K
Vertiflex, Inc.$1K
Relievant Medsystems, Inc.$1K
AbbVie$1K
Nevro Corp.$564
plus $3K from 43 others

What the payments were for

Consulting fees$1,2009%
Travel & lodging$1,82514%
Food & beverage$10,19177%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	90	$3,881
Boston Scientific	159	$2,088
Vertiflex, Inc.	8	$1,406
Relievant Medsystems, Inc.	18	$1,121
AbbVie(2 entities)	80	$1,068
Nevro Corp.	31	$564
Pfizer	41	$469
Abbott	14	$284
Amgen(2 entities)	13	$278
Biohaven Pharmaceutical Holding Company Ltd.	14	$206
Biohaven Pharmaceuticals, Inc.	16	$200
Johnson & Johnson(2 entities)	5	$196
Scilex Pharmaceuticals Inc.	12	$177
Novartis	8	$117
Teva Pharmaceuticals USA, Inc.	8	$113
Nalu Medical, Inc.	1	$111
Globus Medical	6	$94
Fidia Pharma USA Inc.	5	$90
Lilly USA, LLC	5	$71
Almatica Pharma LLC	4	$58
Spinal Simplicity, LLC	1	$40
Neurocrine Biosciences, Inc.	2	$36
Averitas Pharma Inc.	2	$36
Vertex	2	$31
Convatec Inc.	1	$31
Tersera Therapeutics LLC	2	$30
Upsher-smith Laboratories LLC	2	$29
Adamas Pharmaceuticals, Inc.	2	$28
Si-bone, Inc.	2	$28
Assertio Therapeutics, Inc.	2	$27
Radius Health, Inc.	2	$27
Procept Biorobotics Corporation	1	$26
Otsuka America Pharmaceutical, Inc.	1	$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$18
Endo USA, Inc.	1	$18
Saluda Medical Americas, Inc.	1	$17
Bioventus LLC	1	$17
Painteq LLC	1	$17
Harmony Biosciences LLC	1	$16
Progenics Pharmaceuticals, Inc.	1	$15
Merck	1	$15
Axsome Therapeutics, Inc.	1	$14
Baudax Bio Inc.	1	$14
Ironshore Pharmaceuticals Inc.	1	$13
UCB, Inc.	1	$13
Stryker	1	$13
GSK	1	$13
Biodelivery Sciences International, Inc.	1	$12
Rock Medical Orthopedics, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,216 in reported general payments places this provider in the 70th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio →

Medicare billing

Part B allowed, 2024

$326,367

Medicare patients

531

Services billed

23,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Pregabalin	20	$458
Gabapentin	45	$272
Duloxetine Hcl	12	$74

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Findlay

Gladstone McDowellColumbus$701K
Amol SoinDayton$184K
Sara NashiCincinnati$140K
Humam AkbikFairfield$117K
Jaudat MahmoodKent$97K
David WalegaColumbus$75K
Jayesh VallabhColumbus$73K
Omar AliSpringfield$67K
Dustin ReynoldsWesterville$62K
Mark MalinowskiChillicothe$57K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →